Infant Formula War: Profits Over Preemies?

In the high-stakes infant nutrition market, a clinical trial sponsored by Abbott Laboratories highlighted increased complications in preterm infants fed Mead Johnson Nutrition's acidified liquid human milk fortifier. Researchers raised concerns, noting a higher incidence of metabolic acidosis and necrotizing enterocolitis with Mead Johnson's product compared to Abbott's non-acidified fortifier.

Concerns arose as some consent forms for the AL16 study allegedly failed to disclose significant risks like metabolic acidosis and necrotizing enterocolitis to parents. These serious adverse events prompted some monitoring doctors to refuse further enrollment in the study.

Internal documents reveal intense competition between Abbott and Mead Johnson, with companies vying for exclusive hospital contracts. This strategy aims to establish brand loyalty early, as babies fed a certain formula in hospitals often continue using it at home, driving significant revenue.

Lawsuits have been filed by parents alleging that preterm infant formulas caused necrotizing enterocolitis, a severe intestinal condition. While regulatory bodies and manufacturers state there is no conclusive evidence linking these formulas to NEC, the legal battles continue.

Manufacturers argue that specialized formulas are crucial when mother's milk is insufficient. However, a past Mead Johnson-sponsored trial that indicated higher NEC rates with an acidified fortifier was not fully disclosed in its publication.